Feasibility of Extracorporeal Shock Wave Myocardial Revascularization Therapy for Post-Acute Myocardial Infarction Patients and Refractory Angina Pectoris Patients.

Extracorporeal shockwave myocardial revascularization (ESMR) is one of the new treatment options for refractory angina pectoris (RAP), and some studies have indicated its effectiveness. A single-arm prospective trial to assess the feasibility of ESMR using Cardiospec for patients with post-acute myocardial infarction (AMI) and RAP was designed and performed. The patients were treated with 9 sessions of ESMR to the ischemic areas for 9 weeks. The feasibility measures included echocardiography; cardiac magnetic resonance imaging; troponin T, creatine kinase-MB (CK-MB), and brain natriuretic peptide testing; and a Seattle Angina Questionnaire (SAQ) survey. Three post-AMI patients and 3 RAP patients were enrolled. The post-AMI patients had already undergone revascularization with percutaneous coronary intervention (PCI) in the acute phase. In two patients, adverse events requiring admission occurred: one a lumbar disc hernia in a post-AMI patient and the other congestive heart failure resulting in death in an RAP patient. No apparent elevations in CK-MB and troponin T levels during the trial were observed. Echocardiography revealed no remarkable changes of ejection fraction; however, septal E/E' tended to decrease after treatments (11.6 ± 4.8 versus 9.2 ± 2.8, P = 0.08). Concerning the available SAQ scores for two RAP patients, one patient reported improvements in angina frequency and treatment satisfaction and the other reported improvements in physical limitations and angina stability. In this feasibility study, ESMR seems to be a safe treatment for both post-AMI patients and RAP patients. The efficacy of ESMR for post-AMI patients remains to be evaluated with additional studies.

[1]  H. Daida,et al.  Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus , 2015, Cardiovascular Diabetology.

[2]  O. Hess,et al.  Cardiac shock wave therapy for chronic refractory angina pectoris. A prospective placebo-controlled randomized trial. , 2013, Cardiovascular therapeutics.

[3]  Ping Yang,et al.  Randomized and double-blind controlled clinical trial of extracorporeal cardiac shock wave therapy for coronary heart disease , 2013, Heart and Vessels.

[4]  A. Zeiher,et al.  Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. , 2013, JAMA.

[5]  R. Erbel,et al.  The coronary circulation in cardioprotection: more than just one confounder. , 2012, Cardiovascular research.

[6]  A. Laucevičius,et al.  Extracorporeal shockwave myocardial revascularization improves clinical symptoms and left ventricular function in patients with refractory angina , 2012, Coronary artery disease.

[7]  Ching‐Jen Wang,et al.  Extracorporeal Shock Wave Therapy Reverses Ischemia-Related Left Ventricular Dysfunction and Remodeling: Molecular-Cellular and Functional Assessment , 2011, PloS one.

[8]  G. Niccoli,et al.  No-reflow: again prevention is better than treatment. , 2010, European heart journal.

[9]  E. Shkolnik,et al.  Initial clinical experience with extracorporeal shock wave therapy in treatment of ischemic heart failure. , 2010, Congestive heart failure.

[10]  S. Kuriyama,et al.  Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[11]  Arturo Evangelista,et al.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[12]  K. Sunagawa,et al.  Extracorporeal cardiac shock wave therapy improves left ventricular remodeling after acute myocardial infarction in pigs , 2007, Coronary artery disease.

[13]  Maurizio Galderisi,et al.  Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. , 2006, Journal of the American College of Cardiology.

[14]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[15]  S. Mariotto,et al.  Extracorporeal shock waves: from lithotripsy to anti-inflammatory action by NO production. , 2005, Nitric oxide : biology and chemistry.

[16]  Kenji Sunagawa,et al.  Extracorporeal Cardiac Shock Wave Therapy Markedly Ameliorates Ischemia-Induced Myocardial Dysfunction in Pigs in Vivo , 2004, Circulation.

[17]  M. Isobe,et al.  Impact of smoking on coronary microcirculatory resistance in patients with coronary artery disease. , 2015, International heart journal.

[18]  Hiroshi Ito Etiology and clinical implications of microvascular dysfunction in patients with acute myocardial infarction. , 2014, International heart journal.

[19]  W. Fearon,et al.  Invasive coronary microcirculation assessment--current status of index of microcirculatory resistance. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[20]  W. Fearon,et al.  Invasive Coronary Microcirculation Assessment , 2014 .

[21]  Ching‐Jen Wang,et al.  Shock wave therapy applied to rat bone marrow-derived mononuclear cells enhances formation of cells stained positive for CD31 and vascular endothelial growth factor. , 2008, Circulation journal : official journal of the Japanese Circulation Society.